Comprehensive Online Oncology Database
New Medicine Oncology KnowledgeBASE
NEWS
SUBSCRIBER SEARCH
(Requires Login)
NEW DRUG
MARKETED DRUG
COMPANY
TARGETS IN ONCOLOGY
NEWS AND WEBCAST SUMMARIES
COMBINATION TRIALS
  
   1-949-830-0448   info@newmedinc.com   
 
ABOUT nm|OK
nm|OK FREE ACCESS AND DEMO
APPLICATIONS
DESCRIPTION OF MODULES
INQUIRIES AND FEEDBACK
LICENSE AGREEMENT
PRIVACY POLICY
SAMPLE QUERY SCREENS
SAMPLE REPORTS & RECORDS
SOURCES
SUBSCRIPTION INFORMATION
USER GUIDE

PRODUCTS AND SERVICES
FUTURE ONCOLOGY
FEATURED IN-DEPTH REPORTS
CUSTOM REPORT REQUEST

NEWS
NEWS SUMMARIES
LATEST nm|OK UPDATES
nm|OK NEWS RELEASES

SITE MAP
Having trouble finding something?
Use our site map.
 

Latest Updates
July 2008 Targets in Oncology Updates and Additions

  • Activin A receptor type II-like 1 (ACVrL1)
  • Adrenomedullin (ADM)
  • Alpha2ß1 integrin
  • BCL2-like 11 (BCL2L11)
  • CD22
  • Chemokine (C-C motif) ligand 2 (CCL2)
  • Chemokine (C-C motif) receptor 2 (CCr2)
  • A disintegrin and metalloprotease domain 10 (ADAM10)
  • A disintegrin and metalloproteinase domain 17 (ADAM17)
  • Insulin-like growth factor 1 receptor (IGF1r)
  • Integrin alpha 2 (ITGA2)
  • Mesothelin (MSLN)
  • MET
  • PAMP


HOME   |   NEW MEDICINE   |   SITE MAP

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM